Ildiko Lingvay

List of Publications by Year in Descending Order

108 papers	7,460 citations	34 h-index	86 g-index
127 ext. papers	10,452 ext. citations	10.6 avg, IF	6.2 L-index

#	Paper	IF	Citations
108	Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. *Diabetes, Obesity and Metabolism*, **2022**, 24, 94-105	6.7	2
107	Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. *JAMA Network Open*, **2022**, 5, e2148030	10.4	3
106	Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. *Postgraduate Medicine*, **2021**, 1-6	3.7	7
105	Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. *JAMA Internal Medicine*, **2021**, 181, 1562-1574	11.5	10
104	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. *Journal of Medical Virology*, **2021**, 93, 4273-4279	19.7	16
103	Once-Weekly Semaglutide in Adults with Overweight or Obesity. *New England Journal of Medicine*, **2021**, 384, 989	59.2	351
102	Semaglutide 2 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet, The*, **2021**, 397, 971-984	40	109
101	Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes. *Obesity*, **2021**, 29, 829-836	8	4
100	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. *Diabetes Care*, **2021**, 44, 1586-1594	14.6	16
99	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1403-1413	27.4	113
98	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. *Diabetes Care*, **2021**, 44, 1595-1603	14.6	10
97	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1414-1425	27.4	102
96	Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1640-1651	6.7	4
95	Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1). *Journal of the Endocrine Society*, **2021**, 5, A24-A24	0.4	2
94	Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Using Insulin. *Journal of the Endocrine Society*, **2021**, 5, A331-A332	0.4	
93	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). *Journal of the Endocrine Society*, **2021**, 5, A10-A10	0.4	78
92	Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4). *Journal of the Endocrine Society*, **2021**, 5, A63-A64	0.4	78

91	Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2). *Journal of the Endocrine Society*, **2021**, 5, A10-A11	0.4	78
90	Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4). *Journal of the Endocrine Society*, **2021**, 5, A7-A7	0.4	1
89	Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2177-2182	6.7	7
88	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. *Circulation*, **2021**, 144, 74-84	16.7	9
87	Insulin Sensitivity After Living Donor Nephrectomy. *Transplantation Proceedings*, **2021**, 53, 1858-1864	1.1	0
86	Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. *Endocrinology, Diabetes and Metabolism*, **2021**, 4, e00170	2.7	3
85	Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. *Diabetes Therapy*, **2021**, 12, 879-896	3.6	5
84	Novel Trial Design: CHIEF-HF. *Circulation: Heart Failure*, **2021**, 14, e007767	7.6	1
83	An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2513-2520	6.7	2
82	Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. *Lancet Diabetes and Endocrinology,the*, **2021**, 9, 563-574	18.1	11
81	Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply. *JAMA - Journal of the American Medical Association*, **2021**, 326, 1214-1215	27.4	
80	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. *Lancet, The*, **2021**,	40	22
79	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	11
78	Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. *Postgraduate Medicine*, **2020**, 132, 337-345	3.7	2
77	Multilevel Variation in Diabetes Screening Within an Integrated Health System. *Diabetes Care*, **2020**, 43, 1016-1024	14.6	2
76	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. *New England Journal of Medicine*, **2020**, 382, 2493-2503	59.2	100
75	Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience. *Otolaryngology - Head and Neck Surgery*, **2020**, 162, 634-640	5.5	7
74	Trends in the prevalence of cardiometabolic disease and cardiovascular events by body mass index category in adults from 1999 to 2016. *Postgraduate Medical Journal*, **2020**, 96, 655-659	2	3

73	Impact of bariatric surgery on cerebral vascular reactivity and cognitive function: a non-randomized pilot study. *Pilot and Feasibility Studies*, **2020**, 6, 21	1.9	2
72	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2241-2247	6.7	7
71	Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	1
70	Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care. *American Journal of Managed Care*, **2020**, 26, S344-S355	2.1	
69	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. *Diabetes, Obesity and Metabolism*, **2020**, 22, 442-451	6.7	44
68	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. *Diabetologia*, **2020**, 63, 473-485	10.3	11
67	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2248-2256	6.7	2
66	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. *Cardiovascular Diabetology*, **2020**, 19, 156	8.7	10
65	Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. *Clinical Diabetes*, **2020**, 38, 390-402	2.9	12
64	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. *American Heart Journal*, **2020**, 229, 61-69	4.9	53
63	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 analyses. *BMJ Open*, **2020**, 10, e037883	3	3
62	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	5
61	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. *Obesity*, **2020**, 28, 1050-1061	8	77
60	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. *Diabetes and Metabolism*, **2019**, 45, 409-418	5.4	54
59	VISUAL VIGNETTE. *Endocrine Practice*, **2019**, 25, 771	3.2	
58	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care*, **2019**, 42, 2272-2281	14.6	128
57	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. *Diabetes Care*, **2019**, 42, 2262-2271	14.6	82
56	Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 4449-4458	5.6	21

55	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 834-844	18.1	81
54	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. *Cardiovascular Diabetology*, **2019**, 18, 73	8.7	33
53	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet, The*, **2019**, 394, 39-50	40	186
52	A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. *Diabetes, Obesity and Metabolism*, **2019**, 21, 2133-2141	6.7	2
51	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, **2019**, 381, 841-851	59.2	567
50	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. *Diabetes Care*, **2019**, 42, 1454-1463	14.6	28
49	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. *Cardiovascular Diabetology*, **2019**, 18, 156	8.7	6
48	Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. *BMJ Open Diabetes Research and Care*, **2019**, 7, e000761	4.5	13
47	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes and Endocrinology,the*, **2018**, 6, 275-286	18.1	270
46	Metabolic response 4 years after gastric bypass in a complete cohort with type 2 diabetes mellitus. *Diabetes Research and Clinical Practice*, **2018**, 137, 224-230	7.4	4
45	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. *Diabetes/Metabolism Research and Reviews*, **2018**, 34, e2981	7.5	12
44	Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission. *Diabetes, Obesity and Metabolism*, **2018**, 20, 1710-1721	6.7	13
43	Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. *Diabetes, Obesity and Metabolism*, **2018**, 20, 200-205	6.7	9
42	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. *Diabetes Care*, **2018**, 41, 1926-1937	14.6	34
41	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. *Journal of Clinical Endocrinology and Metabolism*, **2018**, 103, 2291-2301	5.6	125
40	Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance. *Journal of Clinical Investigation*, **2018**, 128, 309-322	15.9	52
39	The impact of bariatric surgery on cerebral vascular reactivity. *FASEB Journal*, **2018**, 32, 711.1	0.9	
38	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. *Diabetes, Obesity and Metabolism*, **2018**, 20, 889-897	6.7	114

37	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. *Diabetes Care*, **2018**, 41, 258-266	14.6	208
36	Doc, I Just Ate: Interpreting Random Blood Glucose Values in Patients with Unknown Glycemic Status. *Journal of General Internal Medicine*, **2018**, 33, 142-144	4	4
35	Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide. *Circulation*, **2018**, 137, 2200-2202	16.7	6
34	Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1562-1569	6.7	3
33	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. *Diabetes Technology and Therapeutics*, **2017**, 19, 315-322	8.1	3
32	The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1454-1457	6.7	5
31	Performance of a Random Glucose Case-Finding Strategy to Detect Undiagnosed Diabetes. *American Journal of Preventive Medicine*, **2017**, 52, 710-716	6.1	10
30	SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. *Endocrine Practice*, **2017**, 23, 831-840	3.2	9
29	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. *Current Diabetes Reports*, **2017**, 17, 124	5.6	13
28	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 1834-1844	59.2	2547
27	Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5). *Canadian Journal of Diabetes*, **2016**, 40, S41-S42	2.1	3
26	Effect of Adding Liraglutide vs Placebo to a High-Dose Insulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial. *JAMA Internal Medicine*, **2016**, 176, 939-47	11.5	25
25	Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. *Journal of Clinical Endocrinology and Metabolism*, **2016**, 101, 1798-806	5.6	18
24	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2016**, 315, 898-907	27.4	138
23	Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI. *Journal of Magnetic Resonance Imaging*, **2016**, 44, 1312-1319	5.6	15
22	Random blood glucose: a robust risk factor for type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2015**, 100, 1503-10	5.6	19
21	Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. *Diabetes/Metabolism Research and Reviews*, **2015**, 31, 734-44	7.5	29
20	Comparative Evaluation of Two Venous Sampling Techniques for the Assessment of Pancreatic Insulin and Zinc Release upon Glucose Challenge. *Journal of Diabetes Research*, **2015**, 2015, 789359	3.9	

19	First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case Report. *Journal of Investigative Medicine High Impact Case Reports*, **2015**, 3, 2324709615603723	1.2	2
18	Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial. *Journal of Investigative Medicine*, **2014**, 62, 676-86	2.9	13
17	Rapid improvement in diabetes after gastric bypass surgery: is it the diet or surgery?. *Diabetes Care*, **2013**, 36, 2741-7	14.6	82
16	Brief report: depression and history of suicide attempts in adults with new-onset Type 2 Diabetes. *Psychoneuroendocrinology*, **2013**, 38, 2810-4	5	15
15	The metabolic cost of lowering blood pressure with hydrochlorothiazide. *Diabetology and Metabolic Syndrome*, **2013**, 5, 35	5.6	6
14	Response to Comment on: Harrison et al. Ecell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care 2012;35:1406-1412. *Diabetes Care*, **2013**, 36, e17	14.6	1
13	Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. *Journal of Investigative Medicine*, **2013**, 61, 40-4	2.9	36
12	Effect of insulin versus triple oral therapy on the progression of hepatic steatosis in type 2 diabetes. *Journal of Investigative Medicine*, **2012**, 60, 1059-63	2.9	9
11	Ecell function preservation after 3.5 years of intensive diabetes therapy. *Diabetes Care*, **2012**, 35, 1406-12	14.6	73
10	Pancreatic steatosis and its relationship to Ecell dysfunction in humans: racial and ethnic variations. *Diabetes Care*, **2012**, 35, 2377-83	14.6	85
9	Pancreatic triglyceride levels: implications for type 2 diabetes development in ethnic minorities. *FASEB Journal*, **2012**, 26, 686.20	0.9	
8	Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. *Expert Review of Cardiovascular Therapy*, **2011**, 9, 321-8	2.5	33
7	SweetRs syndrome and subacute thyroiditis: an unrecognized association?. *Thyroid*, **2010**, 20, 1425-6	6.2	3
6	Noninvasive quantification of pancreatic fat in humans. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 4070-6	5.6	144
5	Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?. *Diabetes Care*, **2009**, 32, 1789-95	14.6	67
4	Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2007**, 21, 137-42	3.2	36
3	Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. *Journal of Investigative Medicine*, **2007**, 55, 62-8	2.9	24
2	Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. *Circulation*, **2007**, 116, 1170-5	16.7	458

1	Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. *Journal of Investigative Medicine*, **2007**, 55, 230-6	2.9	53